Скачать или смотреть (Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive...

Full title: (Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive Lung Cancer
Full Lecture: http://www.podcasts.com/society-for-t...
Ibiayi Dagogo-Jack, MD
Massachusetts General Hospital

Full title: (Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive Lung Cancer

To date, analysis of biopsies from progressive lesions has been the primary method of characterizing resistance to ALK TKIs. These analyses have identified acquired ALK resistance mutations in more than half of patients relapsing on a second-generation TKI. This lecture reviews the molecular basis of acquired resistance to next-generation ALK TKIs, discusses the impact of heterogeneity on response to ALK therapies, demonstrates that plasma genotyping reliably detects ALK resistance mutations, and presents emerging data supporting the potential for liquid biopsies to refine current understanding of determinants of ALK TKI response.

This is a brief overview of her talk that occurred during the 2018 Chabner Colloquium.

These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

About The Chabner Colloquium:
Chaired by: Bruce A. Chabner, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School.

This annual Colloquium is held in collaboration with The Massachusetts General Hospital Cancer Center and designed to focus on topics that bring cancer biology to clinical application:
New targets and targeted agents
Strategies for profiling and selection of patients for targeted drug trials
Biomarkers and animal models to guide clinical development